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Abstract 
Leflunomide is a member of the disease modifying anti-rheumatic drugs group used as a treatment modality in 
active rheumatoid and psoriatic arthritis. “Oral ulcers” are reported in 3-5% of leflunomide medicated rheumatoid 
arthritis patients with adverse events, but they are not described in detail in the literature. We present a case of an ul-
cer in the tongue of a rheumatoid arthritis patient managed with leflunomide and contemplate on its pathogenesis.
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Introduction
Leflunomide is a member of the disease modifying anti-
rheumatic drugs group (DMARDs) and is approved by 
Food and Drug Administration as a treatment modality in 
active rheumatoid and psoriatic arthritis. Biochemically, 
it is a pro-drug that rapidly shifts to its active metabolite, 
teriflunomide or A77-1726 (1). Various molecular me-
chanisms of action for teriflunomide are described with 
inhibition of the mitochondrial enzyme dihydroorotate 
dehydrogenase (DHODH) anticipated when the drug is 
administered in immunomodulatory doses. DHODH is 
the key-enzyme in the de novo pyrimidine synthesis pa-
thway, leading to ribonucleotide uridine monophosphate 
(rUMP) formation and promotion of cell proliferation 
through DNA and RNA synthesis enhancement. There-
fore, teriflunomide inhibits proliferation of autoimmune 
T-cells and production of autoantibodies by B-cells (2).
Cutaneous ulcers are reported in rheumatoid arthritis 
patients and thought to have a multifactorial etiology, 
involving rheumatoid vasculitis, increased susceptibility 
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of the skin to trauma due to alterations caused by pro-
longed systemic steroid treatment, and adverse effects 
of DMARDs and non-steroidal anti-inflammatory drugs 
(1-5). Leflunomide-associated cutaneous ulcers are 
considered rare, not preceded by trauma and show non-
specific inflammation on microscopic examination (5,6). 
Adverse reactions of leflunomide in the oral cavity in-
clude oral candidiasis, herpetic infection (7) and “oral 
ulcers” (http://products.sanofi.us/arava/arava.html, revi-
sed February 2016), although the latter are not described 
in rheumatoid arthritis patients (8). 
We present a case of an ulcer in the tongue of a rheu-
matoid arthritis patient medicated with leflunomide that 
microscopically showed severe epithelial dysplasia, and 
contemplate on its pathogenesis.
Case Report
A 59-year-old woman was referred by her dentist for 
diagnosis and management of an ulcerated lesion on the 
tongue. According to the patient, the lesion was first no-
ticed approximately 6 months before presentation and 
showed periods of “exacerbation”, lasting for less than 
15 days, and “remission”. She considered it as a “com-
mon aphthous ulcer” and tried to manage it with local 
application of baking soda. Her medical history inclu-
ded rheumatoid arthritis with inflammatory polyarthritis 
diagnosed approximately 12 years ago and medicated 
with orally administered prednisolone 7.5 mg/day plus 
leflunomide (Arava®, Aventis Pharmaceuticals, Brid-
gewater, NJ) 20mg every day, for the last 6 years. She 
was, also, receiving olmesartan for hypertension and 
atorvastatin for hypecholisteraimia. She did not smoke 
or drink alcohol.
Clinical examination revealed an irregularly shaped ul-
cer covered by fibrinopurulent membrane and partly su-
rrounded by a firmly attached white plaque on the ven-
tral surface of the right side of the tongue (Fig. 1). The 
Fig. 1. Irregularly shaped ulcer covered by fibrinopurulent mem-
brane and partly surrounded by a firmly attached white plaque on 
the ventral surface of the right side of the tongue. Notice small, white 
epithelial shreds around the lesion.
Fig. 2. Ulceration covered by a fibrinopurulent membrane is sur-
rounded by hyperparakeratotic and acanthotic stratified squamous 
epithelium [hematoxylin and eosin stain, original magnification 
x200].
ulcer measured approximately 1x0.5cm and was soft and 
slightly painful on palpation. Small, white epithelial tugs 
around the lesion were easily removed with gauze, while 
the rest of the oral mucosa was within normal limits. The 
lesion was in contact with broken amalgam fillings and 
decayed teeth’s roots. A provisional diagnosis of trau-
matic ulcer and/or lichenoid reaction was rendered and 
complete dental restoration was asked. In addition, oral 
rinses with a dexamethasone oral drops solution 2mg/ml 
x10ml and local applications of a chlorhexidine gel were 
prescribed for 2 weeks. 
The patient presented for re-examination six weeks la-
ter. The amalgam fillings were replaced by composite 
resin fillings and the roots were extracted approxima-
tely 2 weeks ago, while she was still rinsing her mouth 
with the dexamethasone solution, but the lesions persis-
ted. A partial biopsy was requested to establish a diag-
nosis, but she refused to proceed. At that time, on her 
rheumatologist’s advice he discontinued leflunomide 
and on re-examination a month later, a <50% healing 
of the ulcer was evident. Another month later, the ulcer 
had not fully healed and as reinstitution of leflunomide 
at a reduced dosing schedule (10mg/day) was necessary 
due to relapse of rheumatoid arthritis, she consented to 
the biopsy. 
Microscopic examination of formalin-fixed and paraffin-
embedded tissue sections showed an ulceration covered 
by a fibrinopurulent membrane and based by granulation 
tissue (Fig. 2). It was surrounded by hyperparakeratotic 
and acanthotic stratified squamous epithelium, showing 
drop-shaped rete ridges, irregular stratification, loss of 
polarity of basal cells, increased nuclear to cytoplasmic 
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Fig. 3. Atypical features of epithelial cells [hematoxylin and eosin 
stain, original stain, original magnification x400].
ratio, cellular pleomorphism, increased nuclear size, 
increased number and size of nucleoli, dyskeratosis, 
as well as increased number of mitotic figures (Fig. 3). 
Those features occupied the full extent and thickness of 
the epithelium. The underlying connective tissue showed 
dense inflammatory infiltrates of lymphocytes, plasma 
cells and polymorphonuclears, mostly in a band-like 
subepithelial distribution. Atypical cell were not found 
in the connective tissue. A periodic acid-Schiff (PAS) 
stain did not reveal candidal hyphae. A histopathologic 
diagnosis of severe epithelial dysplasia was rendered. 
Therefore, excision of the residual white lesions on cli-
nically healthy margins was performed, confirming the 
initial diagnosis. The healing process was uneventful, 
and six months later the patient is on 20mg/day of leflu-
nomide, while no recurrence or new lesions have deve-
loped. The patient gave her informed consent for the use 
of her data for study.
Discussion
“Oral ulcers” are described in 3-5% of leflunomide-me-
dicated rheumatoid arthritis patients reporting adverse 
events (http://products.sanofi.us/arava/arava.html, revi-
sed February 2016), but this may be a sign of various 
oral diseases, including oral candidiasis and herpetic in-
fection that may be seen in those patients (7).
In the case described herein, the presence of amalgam 
fillings in close proximity to the lesion raised the pos-
sibility of a lichenoid amalgam reaction, but after amal-
gam replacement by composite resin no healing of the 
lesion was evident, while the histologic features of the 
epithelium were not consistent with this diagnosis (9). 
Leflunomide use in rheumatoid arthritis may be rarely 
associated with infections, like oral candidiasis and 
herpetic infection (7), but neither the clinical presenta-
tion nor the microscopic features were consistent with 
a fungal or herpetic disease (9). The ulcer was clearly 
associated with injurious factors, was surrounded by 
hyperkeratotic mucosa as seen in chronic traumatic ul-
cers, while epithelial tugs of traumatic etiology were 
seen in its vicinity. Therefore, it was initially considered 
consistent with a chronic traumatic ulcer, but it did not 
heal following removal of all possible injurious factors 
(9). Withdrawal of leflunomide for a month resulted in 
<50% healing, therefore we consider that the ulcer was 
induced by the local trauma and that healing was inhibi-
ted by leflunomide. 
In particular, the rapid proliferation that is necessary for 
re-epithelialization of a traumatic ulcer requires a sig-
nificant increase in pyrimidine ribonucleotides levels, 
mostly rUMP, in order for the cells to synthesize DNA 
and progress from G1 through the S phase of the cell cy-
cle (2). DHODH inhibition hampers pyrimide synthesis, 
causes G1 phase arrest and restrains healing, although 
in therapeutic doses for rheumatoid arthritis it does not 
cause oral mucositis, as proliferating cells may use sal-
vage pathways for pyrimidine synthesis (3). In addition, 
teriflunomide has the ability to inhibit epidermal growth 
factor-depended cell growth (10).
This pathogenetic mechanism may also explain the pre-
sence of epithelial dysplasia around the ulcer, although 
the diagnosis of an ulcerated oral leukoplakia cannot be 
fully excluded. Alterations similar to oral epithelial dys-
plasia are seen in oral ulcers after chronic methotrexa-
te administration or folate deficiency and described as 
“pseudo-dysplasia” (11). They are caused by the long-
standing effect of drug or non-drug-induced folate de-
ficiency on DNA synthesis and cellular maturation me-
chanisms, as methotrexate mainly inhibits the enzyme 
dihydrofolate reductase and other enzymes in the folate 
pathway, leading to purine and pyrimidine synthesis dis-
ruption and inhibition of cell cycle (11). Interestingly, 
rUMP and other ribonucleotides inhibited by leflunomi-
de are in part responsible for synthesis of deoxyribonu-
cleotides (2). As there are no yet diagnostic features for 
differentiating dysplasia from “pseudo-dysplasia” this 
hypothesis requires further investigation. 
Oral ulcers in rheumatoid arthritis patients medicated 
with leflunomide may be attributed to disturbed re-epi-
thelialization due to the action of the drug on epithelial 
cell proliferation. The detailed description of more cases 
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of “oral ulcers” in those patients is necessary for docu-
menting that oral ulceration is an adverse event associa-
ted with immunomodulatory doses of leflunomide.
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